NeuroVive says COO position is no longer required
Mr. Nilsson also was a Director and for a period he acted as NeuroVive interim CEO. Mr. Nilsson has over 30 years of experience in senior management, commercial and sales roles in the pharmaceutical and biotechnology sectors in Sweden and internationally.
Since 2011 Mr. Nilsson has served as Managing Director of Lipopeptide AB and as Chief Commercial Officer at Pergamum AB, two clinical-stage Swedish biotech companies developing innovative wound treatments based on therapeutic peptides.
Between 2004 and 2009 he served as Managing Director of Tripep AB, a listed Swedish-biotech company developing therapeutic DNA-vaccines against hepatitis B and C.
Prior to that Mr. Nilsson spent several years at Schering-Plough where he served in a number of senior management, marketing and sales positions, including Vice-President for the Nordic region between 2000 and 2004. He has served on the Board of Directors of NeuroVive since 2011.
NeuroVive says that over the past several months, the business strategy and organization have been re-oriented to optimize the way forward. As one consequence the position of COO is no longer required. ■
LATEST MOVES FROM Sweden
- Kristina Franzén new CFO at Bilia
- Immunicum appoints Karin Hoogendoorn as head of CMC
- Kai Wärn proposed as new board member of AB Electrolux
- Even Frydenberg new president & CEO for Scandic
- Christine Lind new CEO of Medivir AB
More inside POST